Bioinformatics approach combined with experimental verification reveals OAS3 gene implicated in paclitaxel resistance in head and neck cancer.
Hasan Onur CaglarAbdulmelik AytatliNeslisah BarlakElanur Aydin KaratasArzu TatarAbdulkadir SahinOmer Faruk KaratasPublished in: Head & neck (2024)
The therapeutic targeting of OAS3 may resensitize PTX-resistant HNSCC cells with high OAS3 expression to PTX treatment.